STOCK TITAN

Adaptive Biotechnologies - ADPT STOCK NEWS

Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.

Adaptive Biotechnologies Corporation (ADPT) is a leader in immune-driven diagnostics, pioneering NGS-based solutions for minimal residual disease detection and immune system mapping. This page serves as the definitive source for official company announcements, financial disclosures, and scientific advancements.

Investors and researchers will find curated updates including earnings reports, regulatory milestones, and partnership developments in precision medicine. Our repository ensures immediate access to press releases about clonoSEQ adoption, clinical trial collaborations, and innovations in immune medicine.

All content is rigorously verified to provide reliable insights into ADPT's strategic direction within the biotechnology sector. Bookmark this page for real-time updates on diagnostic advancements and market-moving developments.

Rhea-AI Summary

Adaptive Biotechnologies presented significant findings at IDWeek 2021 regarding its T-Detect™ COVID test, which can identify previous SARS-CoV-2 infections up to 12 months post-diagnosis. The test also distinguishes between natural infections and vaccine responses, outperforming traditional antibody tests. Additionally, results highlight that TCR repertoire characterization is nearly twice as sensitive as standard tests for identifying Lyme disease. These advancements illustrate the potential for T-cell testing to enhance clinical diagnostics and disease monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) has launched an enhanced clonoSEQ® B-cell Clonality (ID) report, which now includes immunoglobulin heavy chain (IgH) – V mutation status for chronic lymphocytic leukemia (CLL) patients. This report, the only FDA-cleared in vitro diagnostic for detecting and monitoring minimal residual disease (MRD) in CLL, offers dual insights from a single test. Including IGHV mutation status, which correlates with better outcomes, simplifies diagnosis and treatment planning for physicians. The update aims to enhance patient management by providing critical prognostic information at diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
Rhea-AI Summary

Adaptive Biotechnologies has opened its new corporate headquarters and lab in Seattle, designed to foster growth and innovation in biotechnology. The 100,086 square foot facility features over 20,000 square feet of lab space to enhance its diagnostic pipeline and drug discovery efforts. With nearly double the workforce since the pandemic, Adaptive is committed to scaling operations. The company also launched a partnership with STEM Paths Innovation Network to support female students in STEM fields, demonstrating a commitment to diversifying the workforce.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its upcoming presentation at IDWeek 2021, showcasing its immune medicine platform's capacity to differentiate between natural infections and vaccine responses related to SARS-CoV-2. New studies indicate that the T-cell response remains detectable nearly 12 months after positive PCR tests. The T-Detect™ COVID test, the first T-cell-based assay in the U.S., confirms prior infections through whole blood samples. The findings are significant for vaccine efficacy, diagnostics, and ongoing research into immune responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
conferences
-
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the virtual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 8:00 a.m. PT. The company will engage in a fireside chat, accessible via a live and archived webcast on their Investors webpage. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to develop innovative clinical products for disease diagnosis and treatment. The company has three commercial products and a strong clinical pipeline addressing conditions like cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
conferences
-
Rhea-AI Summary

Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Curebase have partnered to enhance patient participation in clinical studies, focusing on Adaptive's T-Detect™ diagnostic test. The collaboration will initially target Lyme disease and COVID-19 patient data collection. With Curebase's decentralized trial model, studies can reach remote populations while preserving patient-provider relationships. The need for modernization in clinical trials is emphasized, particularly in increasing access for underrepresented patient groups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
Rhea-AI Summary

Adaptive Biotechnologies has appointed Nitin Sood as the new chief commercial officer effective immediately. With over 15 years in the diagnostics and life sciences sectors, Sood's experience includes significant roles at Guardant Health and NuGEN. His appointment coincides with Adaptive's strategy for commercial growth and upcoming product launches, including immunoSEQ, clonoSEQ, and T-Detect. CEO Chad Robins emphasized Sood's proven ability to build and scale commercial organizations as vital for the company’s expansion plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
management
-
Rhea-AI Summary

Adaptive Biotechnologies reported financial results for Q2 2021, showcasing 83% revenue growth year-over-year, reaching $38.5 million. Sequencing revenue grew by 132% to $18.6 million, while development revenue rose 53% to $20 million. Despite this growth, the company faced an operating loss of $49.3 million, worsening from $33.5 million in Q2 2020. The company has $689.5 million in cash and expects to generate $148 million to $155 million in revenue for the full year 2021, indicating 54% growth at the midpoint.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
-
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) will release its financial results for Q2 2021 after market close on August 4, 2021. A conference call with management will follow at 1:30 PM PT/4:30 PM ET, accessible via their website. The company focuses on decoding the adaptive immune system to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. They boast three commercial products and a comprehensive clinical pipeline aimed at personalized immune-driven therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences earnings
Rhea-AI Summary

Adaptive Biotechnologies announces the use of its immunoSEQ T-MAP COVID technology in a Nature study demonstrating T-cell immune response to the Johnson & Johnson COVID-19 vaccine against variants like B.1.351. The findings suggest preserved T-cell responses, even as neutralizing antibodies wane, indicating T-cells may offer essential protection from variants. The research underscores the importance of measuring T-cell responses in vaccine trials, especially against emerging strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
covid-19
Adaptive Biotechnologies

Nasdaq:ADPT

ADPT Rankings

ADPT Stock Data

1.09B
143.85M
2.39%
94.01%
5.83%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SEATTLE